A study investigated tau phosphorylation-related targets for Alzheimer's disease treatment, focusing on four kinases and one phosphatase. The model suggests the role of each enzyme in AD pathogenesis and identifies potential targets for therapy. This work builds upon InSysBio's quantitative systems pharmacology (QSP) modeling approach.
A computer model developed by InSysBio scientists suggests that activating beta-amyloid degradation is key to preventing protein plaques in the brain. The model found that starting treatment at age 60 can lead to relative normalization of indices, highlighting the importance of early intervention.
Researchers have developed systems-pharmacological modeling to analyze and predict the dynamics of new drugs for Alzheimer's disease. The models can accurately match cerebrospinal fluid analysis results with brain processes, allowing for optimal drug administration and therapy selection.